Title
Date
16 May, 2025
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
13 May, 2025
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At The Market Under Nasdaq Rules
13 May, 2025
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel Late Stage Abeotaxane TPI 287
01 April, 2025
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
25 March, 2025
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
There are no press releases that match the selected filters.
View More
Stay Updated
Your email alerts were set.
The following alerts could not be set: